Intravitreal Injection

Similar documents
Information for Patients undergoing Intravitreal Triamcinolone Acetonide (Kenalog) Injection

Ophthamology Directorate. Eye Injection for Macular Disorders Information for Patients

Treatment of Age Related Macular Degeneration (AMD) by Intravitreal Injection

Treatment of Retinal Vein Occlusion (RVO)

Information for patients

What is Age-Related Macular Degeneration?

Treatment of wet macular degeneration by intravitreal injection with Ranibizumab (Lucentis) or Aflibercept (Eylea): Information and consent

Age-Related Macular Degeneration (AMD)

Age-related Macular Degeneration (AMD) treatment information

Patient information Eylea treatment for diabetic macular oedema (DMO)

INFORMED CONSENT FOR AVASTIN TM (BEVACIZUMAB) INTRAVITREAL INJECTION

Cataract Surgery. Patient Information. How your care will be organised. Introduction

Introduction How the eye works

Treatment of Diabetic Macular Oedema by Intravitreal Injection with Ranibizumab (Lucentis)

Important: Please read before your appointment

Patient Information Cataract Surgery

The Foundation WHAT IS THE RETINA? continued next page. RETINA HEALTH SERIES Facts from the ASRS

PATIENT INFORMATION LEAFLET. PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM OZURDEX, dexamethasone 700 μg intravitreal implant

Package leaflet: information for the user. OZURDEX 700 micrograms intravitreal implant in applicator dexamethasone

In all cases, a doctor will explain the procedure to you and answer any questions you may have.

Cataract. What is a Cataract?

RETINAL CONDITIONS RETINAL CONDITIONS

A Patient s Guide to Diabetic Retinopathy

Vitrectomy for diabetic vitreous haemorrhage

What you can expect with OZURDEX

Patient Information Argon macular laser treatment Introduction

Photodynamic Therapy (PDT) for agerelated

Facts About Diabetic Eye Disease

ILUVIEN 190 micrograms intravitreal implant in applicator (fluocinolone acetonide)

GENERAL INFORMATION DIABETIC EYE DISEASE

Macular Hole. Helpline

Intravitreal Injections for Wet Age Related Macular Degeneration

Cataract. What is a Cataract?

GHPI0100_06_10 Contact: Ophthalmology Review due: June What is a Cataract?

Cataracts (1 of 7) What is a cataract? What can be done about a cataract? Lens

Cataract and Cataract Surgery

Cataract Surgery. This reference summary will help you understand what cataracts are and how they can be treated surgically.

Information for patients considering cataract surgery Castleton Day Surgery Unit, Yeatman Hospital, Sherborne

Cataract Surgery: Information for patients. Back of eye. Vitreous. Retina. Lens

Preparing for laser treatment for diabetic retinopathy and maculopathy

Cataract = opaque lens

Information for Patients. Vitrectomy

UVEITIS IN GENERAL. Information for patients UVEITIS CLINIC WHAT IS UVEITIS? MAIN CATEGORIES OF UVEITIS

Ophthalmic VEGF Inhibitors. Eylea (aflibercept), Macugen (pegaptanib) Description

Information for Patients. Macular Hole

OP01 Cataract Surgery (Phacoemulsification)

VISIONCARE S IMPLANTABLE MINIATURE TELESCOPE (by Dr. Isaac Lipshitz)

Vitrectomy for diabetic vitreous haemorrhage

Cataract Surgery Patient Information

Macular hole. Information for patients Ophthalmology (Vitreal Retina) Large Print

Trabeculectomy. Corneo-Plastic Unit

Brampton Hurontario Street Brampton, ON L6Y 0P6

CONSENT FOR CATARACT SURGERY REQUEST FOR SURGICAL OPERATION / PROCEDURE AND ANAESTHETIC

Trabeculectomy a treatment of Glaucoma

Here s what you need to know about your treatment with JETREA (ocriplasmin)

Uveitis / Iritis. Introduction. Other formats

Specialist Referral Service Willows Information Sheets. Cataract surgery


Epiretinal membrane. Information for patients Ophthalmology (Vitreal Retina) Large Print

PRECISION PROGRAM. Injection Technique Quick-Reference Guide. Companion booklet for the Video Guide to Injection Technique

Diabetic maculopathy 11/ An update on. Miss Vasuki Sivagnanavel

For further reading we recommend the following excellent textbooks:

Goole & District Hospital Woodland Avenue Goole DN14 6RX

Orbital decompression surgery for proptosis

Ophthalmology. Cataract

Patient Information: Macular Hole Surgery

EYLEA. (aflibercept solution for injection) Patient Guide

Learn Connect Succeed. JCAHPO Regional Meetings 2017

Ophthalmology Patient Information Leaflet

Caregiver s guide to wet AMD

Cataracts are a normal feature of aging. About half of adults aged 65 to 74 have cataracts.

Ganglion impar block. Pain Management Patient Information Leaflet

Sacroiliac joint injections

Superior hypogastric plexus block. Pain Management Patient Information Leaflet

Having a Bronchoscopy

Diabetic Eye Disease

Lumbar sympathetic block. Pain Management Patient Information Leaflet

Patient information. Retinal Detachment Surgery St. Paul s Eye Unit PIF 024 V7

Ankle arthroscopy. If you have any further questions, please speak to a doctor or nurse caring for you

If you would like further information, please ask any of the staff at the clinic. They will be happy to help.

What you can expect with OZURDEX

Cataracts in babies and children

UNDERSTAND MORE ABOUT UVEITIS UVEITIS

Retinal Vein Occlusion (RVO) Treatment pathway- Northeast England. Retinal Vein Occlusion (RVO) with Macular oedema (MO)

Patient Information Leaflet Glaucoma Procedures. Trabeculectomy

Diabetes & Your Eyes

Having a vitrectomy surgery to repair your retinal detachment

Information for Patients. Retinal Detachment

The risks and benefits of cataract surgery

Ruthenium plaque treatment

Scrub In. What is the function of vitreous humor? What does the pupil do when exposed to bright light? a. Maintain eye shape and provide color vision

OAKLEIGH EYE CENTRE. THE EYE Before looking at diabetic retinopathy it is important to understand what the healthy eye looks like and how it works.

Recurrent Corneal Erosion Syndrome

Glaucoma surgery (trabeculectomy)

Retinal Detachment. Patient Information Leaflet. Ophthalmic Day Surgical Unit

Having a kidney biopsy. Information for patients Sheffield Kidney Institute (Renal Unit)

The Human Eye. Cornea Iris. Pupil. Lens. Retina

An Injector s Guide to OZURDEX (dexamethasone intravitreal implant) 0.7 mg

DIABETIC RETINOPATHY

Ophthalmology. Ophthalmology Services

Transcription:

for patients Eye Clinic Ipswich Hospital Tel: 01473 703230 Intravitreal Injection What is an intravitreal injection? An intravitreal injection is the injection of a drug into the vitreous body (the jelly at the back of the eye). It is given through the sclera (the white of the eye). It may be given as a single injection or as a course of treatment where further injections will be required. Cornea Pupil Syringe Lens Retina Macula Optic nerve Why do I need an intravitreal injection? There are many different conditions that may benefit from intravitreal injections and several different drugs that are used for the treatment of eye diseases. Your ophthalmologist will have explained to you why you need to have an intravitreal injection. What drugs are injected? 1 The drugs most commonly used are anti-vegf agents: ranibizumab (Lucentis), aflibercept (Eylea) and bevacizumab (Avastin). These are a relatively new class of drugs used in wet macular degeneration to slow or stop the growth of the abnormal blood vessels and leakage in the back of the eye (macula area of the retina). These drugs are also used to treat leakage at the back of the eye which can happen sometimes when diabetes affects the eye (diabetic macular edema) or following a blocked blood vessel (retinal vein occlusion) in the eye. 2 Anti-inflammatory drugs (steroids) are sometimes used to reduce swelling of the retina, and they are used in different conditions such as diabetic macular edema, retinal vein occlusion, macular degeneration, ocular inflammation (uveitis) and macular edema following intraocular surgery. The drugs used are dexamethasone implant (Ozurdex), triamcinolone, and fluocinolone acetonide implant (Illuvien). Iris Sheet 1 of 3

3 Intra-vitreal antibiotics are used in severe eye infections, and tend to be used in emergency situations. 4 Other drugs: ocriplasmin (Jetrea) etc. Where does the procedure take place? Injections are performed as an outpatient procedure either in the Garrett Anderson Eye Suite (Macular Unit) or in an operating theatre. You will be given the date, time and exact location by letter or telephone call before your admission for treatment. How long will I be in the hospital for the treatment? The preparation and the procedure take about one and a half hours during the treatment only visit. They are performed as an outpatient procedure; that means you go home after the injection and return to normal activities. The length of your stay depends on the need for additional examinations such as: the measurement of your vision, OCT scan, photography, or other tests which may take place on the same day. This can take a morning or afternoon, or sometimes even longer. How do I prepare for the procedure? Make sure you understand the indication along with the potential risks of the procedure. Do not wear eye makeup on the day of the procedure. Inform your doctor if you regularly use eye drops such as glaucoma drops or artificial tears. Notify your doctor of any infection or inflammation in or around your eyes, or if you have a cold or flu. Notify your doctor if you have allergies to iodine, shellfish, or lignocaine. Notify your doctor if you have had a recent stroke or heart attack. Arrange for someone to drive you to and from your appointment.

What does the procedure involve? You will have some local anaesthetic drops put in to numb the front surface of your eye. The skin around your eye will be cleaned with an iodine-based antiseptic solution and we will also instil antiseptic eye drops (Povidone-iodine) before the injection of the drug to reduce the risk of infection. Then you may have either a cotton bud soaked with local anaesthetic inserted at the site of injection (on the white part of the eye beneath the lid) or a local anaesthetic injection. A small clip (speculum) will be used to keep the eye open. The drug is injected through the white of the eye (sclera) into the vitreous body and the entire procedure may take a few minutes. It is important that you keep still and lie as flat as possible. During the injection your vision may suddenly go dark for a second or two. You will then see some black swirls in your vision which gradually disperse after a few days. Will the injection be painful? Although the surface of your eye is numb from the anaesthetic drops, you will probably notice a slight pain when the needle is entering the eye, similar to the needle scratch you feel when blood is drawn from your vein. The pain depends on various factors and some individuals may be more sensitive than others. The speculum (small clip used to keep the eye open) may cause pressure sensation and discomfort in some patients. You may have a sensation of grit in your eye when the anaesthetic drops wear off. This usually settles in a few hours. The benefits of treatment The aim of intra-vitreal therapy is to improve or stabilise your vision. Anti-VEGF therapy (Lucentis, Eylea, Avastin): These injections may not restore vision that has already been lost, and do not always prevent further loss of vision caused by the disease. Every patient is different and one may need ongoing treatment. Unfortunately, the effect of injections can wear off after a few weeks or months. These injections often need to be repeated every 4 6 weeks, sometimes indefinitely. In wet AMD (age-related macular degeneration), the treatment (Lucentis or Eylea injections) is successful in stabilising the vision in about 90% of individuals. Sheet 2 of 3

Risks of treatment As with any medical or surgical procedure, there is a small risk of complications following intravitreal injections. Most complications that might occur are from the injection itself, rather than the drug. For most patients, the benefit of the treatment outweighs the small risk of injection injury. Common side effects Pain during the procedure; red eye (due to bleeding at the point of injection, which clears in a week or two); sore and gritty eye; black blobs or floaters in vision (may last for few days); and increased eye pressure. Some may experience severe pain or gritty sensation after few hours of the procedure which is usually due to a scratch on the cornea (clear window in the front of the eye). This may be due to drying of the surface and irritation from the iodine antiseptic drops and anaesthetic eye drops given at the time of the injection. Intravitreal steroid injections can increase the chances of cataract (the lens of the eye becoming cloudy) and glaucoma (raised pressure and optic nerve damage). Serious side effects Serious complications of the intravitreal injection procedure include retinal detachment, a macular hole, cataract formation and infection (endophthalmitis) within the eye. Any of these serious complications may lead to severe, permanent loss of vision. In the clinical trials of anti-vegf agents (Lucentis, Eylea), these complications occurred at a rate of less than 0.1% of injections (1 in every 1,000 cases). In the case of multiple injections for one patient the collective risk is about 1% (1 in 100). Other serious events such as inflammation within the eye and increased pressure in the eye occurred at a rate of less than 2% (less than 2 out of every 100) in the clinical trials. Systemic side effects There is a theoretical increased risk of experiencing blood clots (such as may cause heart attack or stroke) after intravitreal administration of anti-vegf agents (Lucentis, Eylea, Avastin). However, a low incidence of these events was seen in the clinical trials. Patients with a history of stroke may be at greater risk of having another stroke. If you have had a stroke or heart attack, please discuss this with your eye doctor or nurse.

Instructions following an intravitreal injection There are no special precautions except to avoid rubbing the eye. Instil the antibiotic eye drops or ointment as prescribed. You can instil the antibiotic eye drops more frequently to lubricate your eyes and to alleviate any discomfort during the first few days, if helpful. You can also take your normal pain relief medication to alleviate any discomfort during the first few days. Your vision may be misty for a few days. The floaters or black swirls will gradually disperse but this can take a few days and sometimes weeks (for example with steroid injection). Warning symptoms If the eye becomes very painful, increasingly red or your vision suddenly deteriorates, please telephone the hospital switchboard on 01473 712233 and ask for the Eye Clinic Coordinator (Monday Friday, 8.30 am to 4.30 pm) or call the Garrett Anderson Eye Suite on 01473 702806 or 01473 702807 (Monday Friday, 8.30 am to 5 pm). Outside these hours please telephone the hospital switchboard on 01473 712233 and ask for the eye doctor on-call. Your eye drops / ointment is / are called Please put into the right / left / both eyes times a day for days. Please wash your hands before and after putting in your eye drops / ointment. Sheet 3 of 3

Summary The aim of intravitreal therapy is to stabilise or improve your vision. The outcome depends largely upon your individual eye condition. Your condition may not get better or may become worse despite these injections. Injections into the eye are generally very safe procedures. Rarely side effects may happen and some may be serious. Additional procedures may be needed to treat these complications. Each injection procedure / visit carries similar risk of developing any of the side-effects or complications described above. You must keep the scheduled treatment and monitoring (clinic) appointments so that staff can check the response to treatment and complications. It is not guaranteed that a particular individual will perform the procedure. The doctor / healthcare professional will, however, have the appropriate experience. Issued by: East Suffolk and North Essex NHS Foundation Trust Ipswich Hospital, Heath Road, Ipswich IP4 5PD www.esneft.nhs.uk Please ask if you need this leaflet in an alternative format. DPS: 06728-18(RP) Issue 5: December 2018 Review date: November 2021 East Suffolk and North Essex NHS Foundation Trust, 2008-2018. All rights reserved. Not to be reproduced in whole, or in part, without the permission of the copyright owner.